Men Do Better than Women on Cancer Immunotherapies

(MedPage Today) -- Overall survival improvement twice as great, meta-analysis finds
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news

Related Links:

This article provides an overview of AZD1775, based on English peer-reviewed articles on MEDLINE. The authors highlight the data from the published preclinical and clinical studies. Expert opinion: A majority of the current clinical trials focus on AZD1775 combined with chemotherapy or radiation. Treatment with AZD1775 was tolerated and antitumor activity has been observed, especially in patients with advanced malignancies harboring G1 checkpoint aberrations and/or DNA damage repair defects. Thus, identification of the molecular subtypes that benefit most from the treatment with AZD1775 alone or in combination may provide ...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Publication date: Available online 15 August 2018Source: Pharmacological ResearchAuthor(s): Robert RoskoskiAbstractThe Ras-Raf-MEK-ERK signal transduction cascade is arguably the most important oncogenic pathway in human cancers. Ras-GTP promotes the formation of active homodimers or heterodimers of A-Raf, B-Raf, and C-Raf by an intricate process. These enzymes are protein-serine/threonine kinases that catalyze the phosphorylation and activation of MEK1 and MEK2 which, in turn, catalyze the phosphorylation and activation of ERK1 and ERK2. The latter catalyze the regulatory phosphorylation of dozens of cytosolic and nuclear...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
(NIH/National Cancer Institute) Steven A. Rosenberg, M.D., Ph.D., of the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), has been named a recipient of the 2018 Albany Medical Center Prize in Medicine and Biomedical Research for his leading role in the development of immunotherapy to treat cancer. Dr. Rosenberg will share the honor with fellow immunotherapy researchers James P. Allison, Ph.D., and Carl H. June, M.D.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
We report that some cancers have extensive loss of epigenetic and transcriptional fidelity, characterized widespread spurious transcription and mRNA processing defects (Loss of transcriptional fidelity: LTF+). LTF impairs transcriptional elongation and imposes a highly specific molecular phenotype where pathways regulated by long genes, such as those involved in inflammatory response are consistently impaired in LTF+ tumors. Accordingly LTF blunts inflammatory response and confers resistance to immune mediated anti-tumor attack, and correlates with poor response to immunotherapeutic drugs in renal cell carcinoma and melano...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
ConclusionsOur preclinical results show rapid and transient vaccination-induced increase of FDG uptake within the spleen reflecting immune activation preceding T cell proliferation. FDG-PET/CT in patients is also capable to image this immune activation resulting in a new potential application of FDG-PET/CT to image immune processes in new immunological therapies.
Source: EJNMMI Research - Category: Radiology Source Type: research
Authors: Ignacio RAB, Lin LL, Rajdev L, Chiao E Abstract This review highlights current interventional clinical trials for HIV-associated malignancies (HIVAMs), with emphasis on 4 mechanistic areas: immunomodulatory therapies and gene therapies, including immune checkpoint inhibitors; cytotoxic therapies; novel tumor-targeted and virally targeted therapies in both AIDS-defining and non-AIDS-defining cancers (NADC); and other screening or topical/ablative interventions. A search on ClinicalTrials.gov located 35 trials, including 12 immunomodulatory or gene therapy trials, 6 cytotoxic therapy trials, 10 trials of the...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Conditions:   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Breast Cancer;   Colorectal Cancer;   Melanoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Merkel Cell Carcinoma;   GastroEsophageal Cancer;   Renal Cell Carcinoma Interventions:   Drug: AB928;   Drug: AB122 Sponsor:   Arcus Biosciences, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(American Association for Cancer Research) The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the fourth International Cancer Immunotherapy Conference at the New York Marriott Marquis in New York City, Sept. 30-Oct. 3, 2018.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(National Foundation for Cancer Research) Researchers from Wake Forest Baptist Medical Center and Tianjin Medical University Cancer Institute and Hospital (TMUCIH) have discovered that gastric cancer tissue samples bearing mutation of a specific gene, MUC16, too are associated with higher tumor mutation loads. Also known as tumor mutation burdens, measurement of high genetic mutation rates among cancerous versus healthy tissue has increasingly been shown to correlate with effective response rates to immunotherapy. The knowledge could bode positively for patients with the biomarker present.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
DNA-damaging chemotherapy and radiation therapy are integrated into the treatment paradigm of the majority of cancer patients. Recently, immunotherapy that targets the immunosuppressive interaction between programmed death 1 (PD-1) and its ligand PD-L1 has been approved for malignancies including non–small cell lung cancer, melanoma, and head and neck squamous cell carcinoma. ATR is a DNA damage–signaling kinase activated at damaged replication forks, and ATR kinase inhibitors potentiate the cytotoxicity of DNA-damaging chemotherapies. We show here that the ATR kinase inhibitor AZD6738 combines with conformal r...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Primary Care | Women